Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.
OBJECTIVE
To assess the performance of several non-invasive markers and of our recently proposed stepwise combination algorithms to diagnose significant fibrosis (F > or = 2 by METAVIR) and cirrhosis (F4 by METAVIR) in chronic hepatitis B (CHB).


METHODS
One hundred and ten consecutive patients (80 males, 30 females, mean age: 42.6 +/- 11.3) with CHB undergoing diagnostic liver biopsy were included. AST-to-Platelet ratio (APRI), Fornso index, AST-to-ALT Ratio, Goteborg University Cirrhosis Index (GUCI), Hui's model and Fibrotest were measured on the day of liver biopsy. The performance of these methods and of sequential algorithms combining Fibrotest, APRI and biopsy was defined by positive (PPV) and negative (NPV) predictive values, accuracy and area under the curve (AUC).


RESULTS
PPV for significant fibrosis was excellent (100%) with Forns and high (> 92%) with APRI, GUCI, Fibrotest and Hui. However, significant fibrosis could not be excluded by any marker (NPV < 65%). Fibrotest had the best PPV and NPV for cirrhosis (87% and 90%, respectively). Fibrotest showed the best AUC for both significant fibrosis and cirrhosis (0.85 and 0.76, respectively). Stepwise combination algorithms of APRI, Fibrotest and biopsy showed excellent performance (0.96 AUC, 100% NPV) for significant fibrosis and 0.95 AUC, 98% NPV for cirrhosis, with 50%-80% reduced need for liver biopsy.


CONCLUSIONS
In CHB sequential combination of APRI, Fibrotest and liver biopsy greatly improves the diagnostic performance of the single non-invasive markers. Need for liver biopsy is reduced by 50%-80% but cannot be completely avoided. Non-invasive markers and biopsy should be considered as agonists and not antagonists towards the common goal of estimating liver fibrosis.
Sebastiani
Giada
G
Department of Clinical and Experimental Medicine, University of Padova, Padova 35100, Italy.
Vario
Alessandro
A
Guido
Maria
M
Alberti
Alfredo
A
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000465:Algorithms; D019540:Area Under Curve; D001219:Aspartate Aminotransferases / Q000097:blood; D001706:Biopsy; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications*; D006801:Humans; D008099:Liver / Q000473:pathology*; D008103:Liver Cirrhosis / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged
D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase